FindTrial
Sign In

A pilot, open label, randomised clinical trial assessing the 12 week immunological response in HIV-1 failing subjects receiving monotherapy with emtricitabine 200 mg once a day or emtricitabine 200 mg once a week or lamivudine 300 mg once a day - The Break Study

A pilot, open label, randomised clinical trial assessing the 12 week immunological response in HIV-1 failing subjects receiving monotherapy with emtricitabine 200 mg once a day or emtricitabine 200 mg once a week or lamivudine 300 mg once a day - The Break Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-001681-16-IT
Enrollment
60
Registered
2006-05-25
Start date
2006-06-06
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-Infection MedDRA version: 6.1 Level: PT Classification code 10000565

Interventions

Trade Name: EPIVIR 30 CPR RIV. 300 MG Pharmaceutical Form: Tablet INN or Proposed INN: Lamivudine CAS Number: 134678-17-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration nu

Sponsors

FONDAZIONE NADIR ONLUS
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subject is 18 years old Subject has given written informed consent Subject is in virological failure Subject has a screening CD4 count 8805; 500 cell/mm3 Subject is on a HAART regimen including lamivudine unchanged from at least 12 weeks Screening genotype evidencing Met 184V mutation genotype performed within 90 days before screening Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Subject has positive Hepatitis B surface antigen. Subject has an active opportunistic infection. Subject has been treated with interleukin 2, other immunomodulants or chemotherapeutics in the previous six months Subject is pregnant or wishes to become so.

Design outcomes

Primary

MeasureTime frame
Main Objective: The general aim of the BREAK study is to evaluate whether there is a difference in the 12 week immunological response in HIV-1 failing subjects receiving monotherapy with emtricitabine EMTRIVA 200 mg once a day or emtricitabine EMTRIVA 200 mg once a week or lamivudine EPIVIR 300 mg once a day;Secondary Objective: -proportion of patients not in immunological failure -changes in absolute number and percentages of CD4 and CD8 cell count and HIV-RNA level, -proportion of patients resuming HAART, -proportion of patients with occurrence of B or C CDC events, -proportion of patients maintaining the Met 184V mutation at week 24 or at study discontinuation;Primary end point(s): Primary end-point will be the proportion of patients with immunological response over a 12-week period in the three groups.—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026